FMR1 and ovarian cancer: When the same analysis was repeated for only 15 functionally oncogenic BRCA1/2 mutations, outcomes were very similar, 2/15 (13.3%) low FMR1 alleles in BRCA1/2 mutation carriers and 21/65 (32.3%) in ovarian cancer patients without BRCA1/2 mutations (P = 0.21).